Version 1
: Received: 22 January 2023 / Approved: 24 January 2023 / Online: 24 January 2023 (03:27:37 CET)
Version 2
: Received: 15 February 2023 / Approved: 16 February 2023 / Online: 16 February 2023 (07:54:31 CET)
Version 3
: Received: 3 March 2023 / Approved: 6 March 2023 / Online: 6 March 2023 (01:53:16 CET)
Hendekli, C.M. Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune-Related Adverse Events along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy against Tumor Plasticity. Journal of Cancer Research and Clinical Oncology 2023, doi:10.1007/s00432-023-04718-x.
Hendekli, C.M. Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune-Related Adverse Events along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy against Tumor Plasticity. Journal of Cancer Research and Clinical Oncology 2023, doi:10.1007/s00432-023-04718-x.
Hendekli, C.M. Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune-Related Adverse Events along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy against Tumor Plasticity. Journal of Cancer Research and Clinical Oncology 2023, doi:10.1007/s00432-023-04718-x.
Hendekli, C.M. Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune-Related Adverse Events along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy against Tumor Plasticity. Journal of Cancer Research and Clinical Oncology 2023, doi:10.1007/s00432-023-04718-x.
Abstract
Immune checkpoint inhibition therapy (ICIT) is an emerging field in oncology especially opening new horizons to chemotherapy refractory patients. This paper provides deep insight into immune related adverse events (irAEs) posing a major challenge and drawback to ICIT, and presents right management strategies for very complex complications. Moreover, a strategy is presented to overcome or to delay the progression after initial good response to ICIT in a subset of patients.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
